FDA Approves Keytruda® Plus Pemetrexed and Platinum Chemotherapy for Malignant Pleural Mesothelioma
The U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, as a...
Where Parexel Stands on The Future of Clinical Trials
At the 2024 DPHARM Conference, we had the chance to interview Peyton Howell, CEO of Parexel, and she shared...
Real-World Data in Clinical Trials: Benefits & Privacy Risks
The landscape of clinical trials is experiencing a paradigm shift with the integration of Real-World Data (RWD). Traditionally conducted...
Why Innovation in Big Pharma Is So Slow: Insights from BMS
At the 2023 DPHARM conference, Hassan Kadhim from Bristol-Myers Squibb offered an insightful look into the challenges driving innovation...
AstraZeneca and Moffitt Cancer Center: Oncology Cell Therapy Collaboration
Moffitt Cancer Center and AstraZeneca have forged a strategic partnership to advance the development of cell therapies, particularly CAR-T...
FDA Authorizes Ocrevus Zunovo™: The Revolutionary MS Treatment
The U.S. Food and Drug Administration (FDA) has authorized Ocrevus Zunovo, a new subcutaneous injection, to treat relapsing and...
The Ultimate Guide to Unlocking the Secrets of Patient Monitoring’s Explosive Growth
The globally connected home medical monitoring devices market is expanding rapidly. In 2023, the number of such devices reached...
Drug Development Processes: Growing Demand Drives Growth
The global drug discovery informatics market is projected to reach $4.8 billion by 2030, expanding at a compound annual...
Breakthrough Contraceptive Revolutionizes Male Birth Control
Contraline, a biotechnology company, has secured an exclusive licensing agreement with the Population Council for NES/T Gel, an investigational...
SpectraWave’s HyperVue™ Revolutionizes Imaging, Secures $50M
SpectraWAVE, a medical imaging innovator, has secured $50 million in Series B funding led by Johnson & Johnson Innovation...